CD44 and cancer: Our group recently reported, to our knowledge for the first time, that TF is also expressed on CD133+ and CD24-CD44+ cancer-initiating stem cells and TF can serve as a novel oncotarget for CSC isolated from human cancer cell lines (such as breast, lung, ovarian, head and neck cancer), tumor xenografts and breast cancer patients [16].